YTHDF1 Antibody

What is YTHDF1 and why is it important in cancer research?

YTHDF1 is an N6-methyladenosine (m6A) RNA binding protein that plays crucial roles in cancer progression and immune surveillance. Recent studies demonstrate that YTHDF1 contributes to immunosuppressive tumor microenvironments in multiple cancer types, making it a valuable research target. YTHDF1 expression strongly anticorrelates with interferon-γ-related gene signatures and CD8+ T cell infiltration in colorectal cancer cohorts . Additionally, YTHDF1 has been shown to promote tumor growth via immunosuppressive mechanisms, suggesting its potential as a therapeutic target for enhancing immune checkpoint blockade efficacy .

What sample types can be successfully analyzed using YTHDF1 antibodies?

YTHDF1 antibodies have been validated across multiple sample types including:

• Cell lines: Successfully detected in HeLa, HepG2, and A549 cells via Western blot

• Tumor tissues: Applied in immunohistochemistry on tissue microarrays from gastric cancer patients

• Mouse tumor models: Used to evaluate YTHDF1 expression in syngeneic tumor models including MC38 and CT26 colorectal cancer models

For optimal results in immunohistochemistry applications, a 1:100 dilution has been documented to effectively detect cytoplasmic expression of YTHDF1 in tumor samples .

What are the recommended protocols for YTHDF1 protein detection by Western blot?

For Western blot detection of YTHDF1:

• Cell lysis: Use standard RIPA buffer supplemented with protease inhibitors

• Protein loading: 20-30 μg total protein per lane is typically sufficient

• Antibody dilution: Follow manufacturer's recommendations (typically 1:1000-1:2000)

• Expected molecular weight: Approximately 60-63 kDa

• Positive controls: HeLa, HepG2, and A549 cells show reliable YTHDF1 expression

For specific applications requiring quantitative analysis, include a loading control such as GAPDH or β-actin to normalize expression levels.

How should researchers evaluate YTHDF1 expression in tumor microenvironment studies?

When analyzing YTHDF1 in the context of tumor microenvironment:

• Multiparameter analysis approach:

  • Combine YTHDF1 detection with immune cell markers (CD8, CD4, CD11b, Gr-1)

  • Correlate with functional markers such as IFN-γ and Granzyme B

  • Assess relationship with myeloid-derived suppressor cells (MDSCs)

• Methodology options:

  • Flow cytometry: For simultaneously quantifying YTHDF1 expression and immune cell infiltration

  • Immunohistochemistry/Immunofluorescence: For spatial distribution analysis

  • Single-cell sequencing: For comprehensive cellular heterogeneity assessment

• Scoring system for tissue samples:
  The cytoplasmic expression of YTHDF1 can be evaluated using a combined scoring system:

  • Proportion score: Based on percentage of positive tumor cells (0: none; 1: ≤10%; 2: 10-≤25%; 3: >25%-50%; 4: >50%)

  • Intensity score: Based on staining intensity (0: none; 1: weak; 2: intermediate; 3: strong)

  • Final score: Product of proportion and intensity scores (range: 0-12)

What controls should be included when studying YTHDF1 function in immune regulation?

Robust experimental design for YTHDF1 functional studies should include:

• Genetic controls:

  • YTHDF1 knockout models (complete gene deletion)

  • YTHDF1 knockdown (siRNA or shRNA-mediated)

  • YTHDF1 overexpression systems

  • Wild-type controls matched for genetic background

• Technical controls:

  • Isotype control antibodies for flow cytometry and immunostaining

  • Secondary antibody-only controls

  • Positive control tissues known to express YTHDF1

  • Vehicle controls for any inhibitor studies

• Biological validation approaches:

  • Parallel in vitro and in vivo experiments

  • Multiple cell lines or primary samples

  • Functional readouts such as T cell activation markers and cytokine production

How can researchers effectively generate YTHDF1 expression constructs for functional studies?

For cloning and expressing YTHDF1:

• Primer design strategy:

  • Include protective bases (e.g., CCG) at 5' ends

  • Add appropriate restriction enzyme sites (e.g., XhoI, EcoRI)

  • Example forward primer: 5'-CCGCTCGAGATGTCGGCCACCAGCGTGGA-3'

  • Example reverse primer: 5'-CCGGAATTCTCATTGTTTGTTTCGACTCTGC-3'

• Expression vector selection:

  • pcDNA3.1 with epitope tags (Myc-His) enables detection and purification

  • Lentiviral vectors for stable expression or difficult-to-transfect cells

  • Inducible expression systems for temporal control

• Restriction digestion protocol:

  • Reaction mixture (20 μl): 2 μl buffer, 1 μl each restriction enzyme, 2 μg fragment or 1 μg vector, ddH₂O

  • Incubate at 37°C for 2 hours

  • Perform ligation with T4 ligase (16 hours at 16°C)

• Verification steps:

  • Sequencing confirmation

  • Western blot to verify expression and correct molecular weight

  • Functional validation through rescue experiments in YTHDF1-knockout models

What methodologies are recommended for analyzing YTHDF1-regulated gene expression?

For comprehensive analysis of YTHDF1-regulated transcripts:

• Integrative sequencing approach:

  • MeRIP-seq: To identify m6A-modified transcripts bound by YTHDF1

  • RNA-seq: To determine transcript abundance changes

  • Ribo-seq: To assess translational efficiency alterations
    This combined approach successfully identified p65/RELA as a YTHDF1 target, revealing the YTHDF1-m6A-p65-CXCL1 axis in colorectal cancer

• RT-qPCR validation protocol:

  • Sample preparation: Homogenize tissue samples with 1 mL TRIzol per 50 mg tissue, or 1 mL per 10⁶ cells

  • RNA quality assessment: Verify using Nanodrop or Bioanalyzer

  • cDNA synthesis: Use PrimeScript RT reagent kit plus gDNA eraser

  • qPCR: Perform using appropriate detection system with proper controls

• Protein-RNA interaction studies:

  • RNA immunoprecipitation (RIP) to identify direct YTHDF1-bound transcripts

  • Crosslinking immunoprecipitation (CLIP) for high-resolution binding site mapping

  • Luciferase reporter assays to validate functional impact on specific transcripts

How can YTHDF1 antibodies be utilized in patient stratification for immunotherapy?

YTHDF1 expression analysis offers potential for patient stratification in immunotherapy:

• Clinical correlation approach:

  • High YTHDF1 expression in dendritic cells correlates with poor progression-free survival in non-small cell lung cancer patients receiving radiotherapy (p=0.0188)

  • YTHDF1 expression inversely correlates with IFN-γ gene signatures and CD8+ T cell infiltration in colorectal cancer patients

• Implementation strategy:

  • IHC scoring of YTHDF1 in patient biopsies using validated antibodies

  • Correlation with immune cell infiltration markers

  • Integration with other predictive biomarkers for immune checkpoint blockade

• Multi-parameter analysis:

  • Combine YTHDF1 expression with PD-L1 status and tumor mutation burden

  • Assess YTHDF1 expression specifically in dendritic cells within tumor microenvironment

  • Correlate with clinical outcomes including response rate and progression-free survival

What are the methodological considerations for targeting YTHDF1 in combination with immunotherapies?

When designing experiments to evaluate YTHDF1 targeting in combination with immunotherapy:

• Therapeutic approaches to inhibit YTHDF1:

  • CRISPR-based gene editing for preclinical models

  • siRNA delivery via nanoparticles (VNPs-siYTHDF1)

  • Small molecule inhibitors targeting YTHDF1-m6A interactions

• Experimental models for combination therapy assessment:

  • MSI-H and MSS colorectal cancer models to evaluate anti-PD1 efficacy enhancement

  • CD34+ humanized mouse models for translational relevance

  • Syngeneic models evaluating YTHDF1 targeting plus radiation and immunotherapy

• Mechanistic investigation:

  • Evaluate USP5 inhibition as a strategy to destabilize YTHDF1 protein

  • Assess changes in K11-linked polyubiquitination of YTHDF1

  • Monitor effects on downstream pathways including STING-dependent type I IFN production in dendritic cells

How can researchers overcome common issues with YTHDF1 antibody specificity and sensitivity?

For optimizing YTHDF1 antibody performance:

• Specificity validation approaches:

  • Perform parallel detection in YTHDF1 knockout/knockdown samples

  • Compare multiple antibody clones targeting different epitopes

  • Pre-adsorption tests with recombinant YTHDF1 protein

  • Evaluate cross-reactivity with other YTH domain family members

• Sensitivity enhancement strategies:

  • Signal amplification systems for low abundance detection

  • Optimized antigen retrieval for fixed tissues (citrate vs. EDTA-based buffers)

  • Extended primary antibody incubation (overnight at 4°C)

  • Use automated staining platforms for consistent results

• Application-specific optimization:

  • For IHC: Test various fixation protocols and antigen retrieval methods

  • For flow cytometry: Optimize permeabilization conditions for intracellular detection

  • For IP applications: Test different lysis buffers and binding conditions

What analytical approaches are recommended for quantifying YTHDF1 expression in heterogeneous tumor samples?

For accurate YTHDF1 quantification in complex tumor samples:

• Cell type-specific analysis:

  • Single-cell RNA sequencing to delineate expression across cell populations

  • Multiplex immunofluorescence to assess co-localization with cell-type markers

  • Flow cytometry with cell sorting for population-specific quantification

• Digital pathology approaches:

  • Whole slide imaging with automated scoring algorithms

  • Standardized intensity thresholds based on control samples

  • Machine learning-based image analysis for pattern recognition

• Correlation with immune infiltrates:

  • Use tools like TIMER2.0 for bioinformatic estimation of immune cell infiltration

  • Calculate Spearman correlations between YTHDF1 expression and immune cell abundance

  • Analyze the impact of YTHDF1 copy number alterations on immune infiltration levels

What emerging applications of YTHDF1 antibodies should researchers consider?

Cutting-edge applications for YTHDF1 research include:

• Spatial transcriptomics integration:

  • Combining YTHDF1 protein detection with spatial RNA analysis

  • Mapping m6A modification patterns in relation to YTHDF1 localization

  • Correlating with spatial distribution of immune cell populations

• Post-translational modification analysis:

  • Investigating ubiquitination patterns affecting YTHDF1 stability

  • Examining the role of USP5 in removing K11-linked polyubiquitination

  • Exploring how mTORC1-mediated phosphorylation of USP5 affects YTHDF1 stability

• Therapeutic targeting strategies:

  • Development of YTHDF1-targeted dendritic cell vaccines

  • Combination approaches with radiation therapy and immune checkpoint blockade

  • Disruption of the YTHDF1-USP5 interaction to enhance immunotherapy response

How might researchers investigate contradictory findings about YTHDF1 function across different cancer types?

To address inconsistencies in YTHDF1 research:

• Comparative analysis approach:

  • Systematic evaluation across multiple cancer types using identical methodologies

  • Side-by-side comparison of YTHDF1 function in different immune cell populations

  • Standardized assessment of m6A target transcripts in various cellular contexts

• Context-dependent mechanism investigation:

  • Evaluate the impact of tumor-specific mutations on YTHDF1 function

  • Assess the influence of the surrounding microenvironment on YTHDF1 activity

  • Examine potential compensatory mechanisms by other m6A readers

• Technological considerations:

  • Application of CRISPR-based screens to identify context-specific cofactors

  • Development of cell type-specific conditional knockout models

  • Use of patient-derived organoids to maintain tumor heterogeneity